외환 뉴스

Swiss Market Ends Sharply Lower

Swiss Market Ends Sharply Lower

After opening modestly higher and spending some time in positive territory Tuesday morning, the Switzerland stock market fell into the red and stayed weak right through the day's session amid rising fears about a possible recession.
RTTNews | 1128 일 전
European Stocks Close Sharply Lower On Recession Fears

European Stocks Close Sharply Lower On Recession Fears

European stocks tumbled on Tuesday as recession fears triggered a sell-off. Investors digested some weak economic data from the Eurozone, and the Bank of England's Financial Stability Report that showed the growth outlook has worsened.
RTTNews | 1128 일 전
Syros Pharmaceuticals To Acquire TYME Technologies

Syros Pharmaceuticals To Acquire TYME Technologies

Syros Pharmaceuticals (SYRS) and TYME Technologies, Inc. (TYME) announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-down and transaction expenses is currently estimated to be approximately $60 million.
RTTNews | 1128 일 전
more news
DURECT Appoints Timothy Papp As New CFO

DURECT Appoints Timothy Papp As New CFO

Biopharmaceutical company DURECT Corp. (DRRX) announced Tuesday the appointment of Timothy Papp as its Chief Financial Officer. Papp brings over 25 years of corporate finance experience to DURECT, including 15 years in the Biopharma sector.
RTTNews | 1128 일 전
Bay Street Likely To Open On Negative Note

Bay Street Likely To Open On Negative Note

Lower Canadian and U.S. futures, weakness in European markets and sluggish commodity prices point to a negative start for Canadian shares on Tuesday.
RTTNews | 1128 일 전
Titan Pharma Says FDA Clears IND Application For Nalmefene Implant

Titan Pharma Says FDA Clears IND Application For Nalmefene Implant

Titan Pharmaceuticals, Inc. (TTNP) announced Tuesday that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene, an opioid antagonist, intended for the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder (OUD).
RTTNews | 1128 일 전

Stay up to date!

Add 뉴스 to your browser

Extension Picture